Enhancement of hemoglobin and F-cell production by targeting growth inhibition and differentiation of K562 cells with ribonucleotide reductase inhibitors (didox and trimidox) in combination with streptozotocin

American Journal of Hematology

Volumn 63, Issue 4, 2000, Pages 176-183

  Iyamu, W E ^a,b   Adunyah, S E ^a   Fasold, H ^c   Horiuchi, K ^b   Elford, H L ^d   Asakura, T ^b   Turner, E A ^a  

^a MEHARRY MEDICAL COLLEGE   (United States)

^b CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^c GOETHE UNIVERSITY   (Germany)

^d Molecules for Health   (United States)

Author keywords

Erythroleukemia cells; Ribonucleotide reductase inhibitors; Sickle cell anemia

Indexed keywords

3,4 DIHYDROXYBENZOHYDROXAMIC ACID; 3,4,5 TRIHYDROXYBENZOHYDROXAMIDOXIME; ANTIANEMIC AGENT; HEMOGLOBIN F; RIBONUCLEOTIDE REDUCTASE; STREPTOZOCIN; UNCLASSIFIED DRUG;

ARTICLE; CELL DIFFERENTIATION; CELL GROWTH; CELL MATURATION; CELL STRUCTURE; CONTROLLED STUDY; DRUG EFFECT; DRUG POTENTIATION; ERYTHROID CELL; ERYTHROLEUKEMIA CELL; GROWTH INHIBITION; HEMOGLOBIN SYNTHESIS; HUMAN; HUMAN CELL; PRIORITY JOURNAL; SICKLE CELL ANEMIA;

ANTINEOPLASTIC AGENTS; BENZAMIDINES; CELL DIFFERENTIATION; CELL DIVISION; DRUG THERAPY, COMBINATION; ENZYME INHIBITORS; FETAL HEMOGLOBIN; HEMOGLOBIN, SICKLE; HUMANS; HYDROXAMIC ACIDS; K562 CELLS; RIBONUCLEOTIDE REDUCTASES; STREPTOZOCIN;

EID: 0034020752     PISSN: 03618609     EISSN: None     Source Type: Journal    
DOI: 10.1002/(SICI)1096-8652(200004)63:4<176::AID-AJH3>3.0.CO;2-G     Document Type: Article

References (32)

1. Schechter AN, Noguchi CT, Rodgers GP. Sickle cell anemia. In: Molecular basis of blood diseases. Stamatoyannaopoulos G, Nienhuis AW, Leder P, Majerus PW, editors. Philadelphia: Saunders; 1987. p 187.
2. Noguchi CT, Schechter AN: The intracellular polymerization of sickle hemoglobin and its relevance to sickle cell disease. Blood 1981;58: 1057.
3. Letvin NL, Linch DC, Beardsley GP, McIntyre KW, Nathan DG. Augmentation of fetal-hemoglobin production in anemic monkeys by hydroxyurea. N Engl J Med 1984;310:869.
4. Fibach E, Burk LP, Schechter AN, Noguchi CT, Rodgers GP. Hydroxyurea increases fetal hemoglobin in cultured erythroids cells derived from normal individuals and patients with sickle cell anemia or β-thalassemia. Blood 1993;81:1630.
5. DeSimone J, Heller P, Hall L, Wiers DZ. 5-Azacytidine stimulates fetal hemoglobin synthesis in anemic baboons. Proc Natl Acad Sci USA 1982;79:4428.
6. Perrine SP, Ginder GD, Faller DV, Dover GH, Ikuta T, Witkowska HE, Cai S, Vishinsky EP Olivieri NF. A short-term trial of butyrate to stimulate fetal-globin-gene expression in the β-globin disorders. N Engl J Med 1993;328:81.
7. Elford H: Effect of hydroxyurea on ribonucleotide reductase. Biochem Biophys Res Commun 1968;33:129.
8. Elford HL, Wampler B, van't Riet. New ribonucleotide reductase inhibitors with antineoplastic activity. Cancer Res 1979;39:844.
9. Veale DM, Carmicheal J, Cantwell BMJ, Elford HL, Blackie R, Kerr DJ, Kaye SB, Harris AL. A phase I and pharmacokinetic study of didox: A ribonucleotide reductase inhibitor. Br J Cancer 1988;58:70.
10. Szekeres T, Gharehbaghi K, Fritzer M, Woody M, Srivastava A, van't Riet B, Jararam NH, Elford HL. Biochemical and antitumor activity of trimidox, a new generation of ribonucleotide reductase inhibitor. Cancer Chemother Pharmacol 1994;34:63.
11. Pace BS, Elford HL, Stamatoyannopoulos G. Transgenic mouse model of pharmacological induction of fetal hemoglobin: Studies using a new ribonucleotide reductase inhibitors, didox. Am J Hematol 1994;45: 136.
12. Iyamu WE, Adunyah SE, Elford HL, Fasold H, Turner EA. Trimidox-mediated morphological changes during erythroid differentiation is associated with the stimulation of hemoglobin and F-cell production in human K562 cells. Biochem Biophys Res Commun 1998;247:759.
13. Arwich A, Fletcher W, Klotz J, et al. 5-FU versus combination therapy with tubercidin, streptozotocin, and 5-FU in the treatment of pancreatic carcinomas. J Surg Oncol 1979;12:267.
14. 6-methyltransferase-mediated nimustin resistance in recurrent malignant gliomas by streptozotocin: A preliminary report. Anticancer Res 1995;15:645.
15. Schein P, Kahn R, Gordon P, Wells S, DeVita V. Streptozotocin for malignant insulinomas and carcinoid tumor. Arch Intern Med 1973; 132:555.
16. DeVita VT Jr. Principle of chemotherapy. In: DeVita VT Jr, Hellman S, Rosenberg SA, editors. Cancer, principles and practice of oncology. Philadelphia: Lippincott, 1989.
17. van't Ried B, Wampler GL, Elford HL. Synthesis of hydroxy amino-substituted benzohydroxamic acids: Inhibition of ribonucleotide reductase and antitumor activity. J Med Chem 1979;22:589.
18. Chou T, Talalay P. Quantitative analysis of dose-effect relationships: The combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 1984;22:27.
19. McLeod DL, Shreeve MM, Axelrad AA. Improved plasma culture system for production of erythrocytic colonies in vitro: Quantitative assay method for CFU-E. Blood 1974;44:517.
20. Horiuchi K, Fynn-Thompson F, Ohene-Frempong K. Degree of ireversible deformation of Hb F cells and non-F-cells from patients with sickle cell disease. Exp Hematol 1994;22:1058-1063.
21. Horiuchi K, Osterhout M, Bekoe N, Kamma H, Hirokawa K. Estimation of Hb F levels in individual red cells by fluorescence image cytometry. Cytometry 1995;20:261-267.
22. Horiuchi K, Osterhout ML, Ohene-Frempong K. Survival of F-reticulocytes in sickle cell disease. Biochem Biophys Res Commun 1995;217:924-930.
23. Reilly MP, Chomo MJ, Ohata K, Asakura T. Red blood cell membrane and density changes under ambient and hypoxic conditions in transgenic mice producing human sickle hemoglobin. Exp Hematol 1994; 22:501-509.
24. Elford HL, van't Riet B. The inhibition of nucleoside diphosphate reductase by hydroxybenzohydroxamic acid derivatives. In: Cory JD, Cory AH, editors. Inhibitors of ribonucleoside diphosphate reductase activity. Oxford: Pergamon; 1989. p 217.
25. Charache S, Terrin ML, Moore RD, Dover G, Barton F, Eckert S, Mcmahon R, Bonds D. Effects of hydroxyurea on the frequency of painful crises in sickle cell anemia and the investigators of the multicenter study of hydroxyurea in sickle cell anemia. N Engl J Med 1995;332:1317.
26. Iyamu EW, Roa PD, Kopsombut P, Aguinaga MdP, Turner EA: New isocratic high performance liquid chromatographic procedure to assay the anti-sickling compound hydroxyurea with ultraviolet detection system. J Chromatogr B 1998;709:119.
27. Moore EC, Hubert RB. The inhibition of ribonucleoside diphosphate reductase by hydroxyurea, guanazole and pyrozoloimidazole) (IMPY). In: Cory JG, Cory AH, editors. International encyclopedia of pharmacology and therapeutics, Oxford: Pergamon: 1989. p 165.
28. Charache S. Fetal hemoglobin, sickling and sickle cell disease. Adv Pediatr 1990;37:1.
29. Charache S, Dover GH, Moore RD, Eckert S, Ballas SK, Kashy M, Milner PFA, Orringer EP, Phillips G, Platt OS, Thomas GH. Hydroxyurea effects on hemoglobin F production in patients with sickle cell anemia. Blood 1992;79:2555.
30. Desesso JM, Scialli AR, Goerringer GC. D-Mannitol, a specific hydroxyl free radical scavenger, reduces the developmental toxicity of hydroxyurea in rabbits. Teratology 1994;49:248.
31. Ding M, Dyke CM, abd-Elfattah AS, Lehman JD, Dignan RJ, Wechsler AS. Efficacy of hydroxyl radical scavenger (VF 233) in preventing reperfusion injury in isolated rabbit heart. Ann Thorac Surg 1992;53:1091.
32. Veith R, Galanello R. Papayannopoulou T, Stammatoyannopoulos G. Stimulation of F-cell production in patients with sickle cell anemia treated with cytarabine or hydroxyurea. N Engl J Med 1985;313:1571.